For research use only
| Cat No. | ABC-X0007C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocyte |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
The ETV6-NTRK2 (G639R) BAF3 cell line provides a stable gene overexpression model for malignant tumor research. Discover our custom services.
Human ETV6-NTRK2 (G639R) BAF3 Cell Line is a genetically engineered model derived from selected murine Ba/F3 parental cell line based on customers’ requirement. ETV6-NTRK2 (G639R) BAF3 fusion cell line is generated by stable integration of exogenous human ETV6-NTRK2 fusion gene harboring the G639R point mutation into Ba/F3 host cells using our optimized transduction of lentiviral vectors.ETV6-NTRK2 fusions and their kinase-activating mutations are implicated in various malignancies, including congenital fibrosarcoma, leukemia, and thyroid carcinoma. AcceGen offers generation of stable overexpression and fusion gene cell lines targeting any gene or mutation of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0007C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO₂ |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The Human ETV6 NTRK2 (G639R) BAF3 Cell Line provides a functional model for exploring the role of mutant NTRK2 fusion proteins in cancer pathogenesis and drug response. The ETV6-NTRK2 fusion, particularly with the G639R point mutation, has been associated with oncogenic transformation and therapeutic resistance. This model supports high-throughput screening of TRK inhibitors, mechanistic studies of aberrant TRK signaling, and investigation of mutation-driven resistance to targeted therapies in hematologic and solid tumors.